Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

American Journal of Hematology

Volumn 84, Issue 12, 2009, Pages 799-802

  Lacy, Martha Q ^a   Mandrekar, Sumithra ^a   Dispenzieri, Angela ^a   Hayman, Suzanne ^a   Kumar, Shaji ^a   Buadi, Francis ^a   Dingli, David ^a   Litzow, Mark ^a   Wettstein, Peter ^a   Padley, Douglas ^a   Kabat, Brian ^a   Gastineau, Dennis ^a   Rajkumar, S Vincent ^a   Gertz, Morie A ^a  

^a Mayo Clinic   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC 8020; IMMUNOGLOBULIN IDIOTYPE; MULTIPLE MYELOMA VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADULT; AGED; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; COHORT STUDIES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN IDIOTYPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 73349121252     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21560     Document Type: Article

References (24)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
2. Salmon S. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 1973;10:136-147.
3. Oken MM, Leong T, Lenhard RE Jr, et al. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Cancer 1999;86:957-968.
4. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129-3135.
5. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-58.
6. Lacy MQ, Gertz MA, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184.
7. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-4053.
8. Richardson PG, Barlogie B, Berenson J, et al. A phase II multicenter study of the proteasome inhibitor bortezomib (VELCADETM, Formerly PS-341) in multiple myeloma patients (pts) with relapsed/refractory disease. Blood 2002; 100:104a(A385).
9. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934.
10. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132.
11. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J 2007;357:2133-2142.
12. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579-585.
13. Kay NE, Leong T, Kyle RA, et al. Circulating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial. Blood 1997;90:340-345.
14. Kay NE, Leong T, Bone N, et al. Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. Blood 2001;98: 23-28.
15. Kay N, Leong T, Kyle RA, et al. Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487). Leuk Lymphoma 1999;33:127-133.
16. Osterborg A, Nilsson B, Bjorkholm M, et al. Natural killer cell activity in monoclonal gammopathies: Relation to disease activity. Eur J Haematol 1990;45:153-157.
17. Dianzani U, Pileri A, Boccadoro M, et al. Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status. Blood 1988;72:1064-1068.
18. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-1020.
19. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-683.
20. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Haematol 2000;108:805-816.
21. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-222.
22. Cull G, Durrant L, Stainer C, et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999;107:648-655.
23. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-A feasibility study. Blood 1999;93:2411-2419.
24. Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J Urol 2005;23:47-49.